The deal with NBE includes a $25 million upfront payment ... a license to an ADC developed by Iconic Therapeutics – called ICON-2 – which targets the tissue factor (TF) pathway thought to ...
NBE-Therapeutics’ immune-stimulatory antibody drug conjugates (iADCs) have a novel mode of action that makes them uniquely well-equipped to fight cancer. iADCs target and destroy cancer cells ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback